ANTEOTECH LTD — Capital/Financing Update 2012

Mar 12, 2012

==> picture [211 x 115] intentionally omitted <==

13th March 2012

Company’s Announcement Office ASX Limited Exchange Centre 20 Bridge Street Sydney NSW 2000

Anteo signs licensing agreement with leading Life Science Company

• Agreement for the licensing of Mix&Go®™ technology with eBioscience

• Licensing arrangement for all global markets

• eBioscience operates in 70 countries and a recognised leader in Life Science reagents

• Agreement moves Mix&Go®™up value chain to test manufacturers

• Healthy pipeline of potential commercial agreements

13 March 2012: Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that it has signed a Patent and Technology License Agreement with eBioscience, a leading US headquartered Life Sciences company, providing them with access to Anteo’s unique Mix&Go®™technology.

Under the terms of the agreement, Anteo will supply Mix&Go®™for use in the manufacture of biological reagents for all applicable markets in which the company operates. Anteo will receive an initial upfront payment, fixed revenue for Mix&Go®™reagent supplied, and a royalty fee paid quarterly based on a percentage of worldwide net sales.

eBioscience has undertaken technical assessment of the Mix&Go®™technology, performed due diligence and reached an agreement with great efficiency. This pleasing outcome could only occur with goodwill from both parties. Further, Anteo expects to be working in close collaboration with eBioscience into the future to ensure that all products that incorporate Mix&Go®™are delivered to the market promptly, that the technology is used broadly across the eBioscience product range and that where applicable, Mix&Go®™is used in new products.

Anteo’s Chief Executive Officer Dr. Geoff Cumming said: “This is a very pleasing development for Anteo and represents a significant commercial opportunity for the company. eBioscience is a recognised global leader

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

==> picture [211 x 115] intentionally omitted <==

in Life Science reagents with a large customer base. To be entering into commercial agreements with market leaders such as eBioscience is further validation of the Mix&Go®™technology.

“Additionally, the agreement signifies for Anteo a transition up the value chain from bead manufacturers to test manufacturers, in accordance with our company’s business strategy.

“Anteo will receive an immediate upfront payment and we consider that a successful partnership with eBioscience will significantly contribute towards allowing us to meet our corporate objectives.

“Anteo is in excellent shape and the Board has sound reasons for continued optimism, with the company in active, and in some case advanced, discussions with a range of other parties that are assessing the merits of the Mix&Go®™technology. These negotiations are ongoing and positive and we are committed to building a pipeline of commercial supply agreements across a range of healthcare sectors to build and diversify our revenue streams.”

Don Tartre, President and CEO of eBioscience, said: “We are pleased to work in partnership with the Anteo Diagnostics team to exploit an innovative technology to leverage our FlowCytomix™bead-based immunoassay product line to even higher performance including greater sensitivity. This is yet another way by which eBioscience looks to deliver to its customers innovative products that demonstrate superior performance.”

About Anteo Diagnostics Ltd

Anteo Diagnostics (www.anteodx.com) is an Australian company developing proprietary surface coatings for applications in the Diagnostics and Life Science industries. The product family, called Mix&Go®™, enables the fast, easy and stable attachment of biomolecules such as antibodies, streptavidin and other proteins to a variety of synthetic surfaces including beads, slides and plates. Anteo actively pursues commercial opportunities across healthcare and a broad array of other sectors for its patented technology. Anteo Diagnostics, founded in 2005, headquartered in Brisbane, Queensland, Australia is traded on the Australian Securities Exchange (ASX:ADO).

About eBioscience, Inc.

Founded in 1999, eBioscience®, a privately held company, is headquartered in San Diego, California and conducts business in more than 70 countries around the world. eBioscience offers a full spectrum of over 11,000 high quality reagents including eFluor® multicolor flow cytometry reagents, FlowCytomix™ bead based immunoassays, Platinum™ and Instant ELISA® brands. eBioscience’s innovative solutions provide researchers with tools to perform comprehensive cell analysis for academic and government institutions and pharmaceutical and biotechnology companies worldwide that empower the process of scientific discovery in the areas of immunology and oncology.

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

==> picture [211 x 115] intentionally omitted <==

For More Information Contact Dr Geoff Cumming, CEO Anteo Diagnostics Limited Tel: +61 2 8823 3110

Sam Sloane Six Degrees Investor Relations Tel: +61 2 9230 0661 or +61 412 845 920

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com